Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1990 1
1991 1
1992 2
1993 2
1994 2
1996 2
1997 3
1998 4
1999 2
2000 1
2001 7
2002 4
2003 5
2004 3
2005 5
2006 3
2007 5
2008 7
2009 13
2010 12
2011 5
2012 10
2013 5
2014 5
2015 6
2016 5
2017 5
2018 10
2019 7
2020 10
2021 10
2022 5
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

162 results

Results by year

Filters applied: . Clear all
Page 1
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH; ESC Scientific Document Group. Lyon AR, et al. Eur Heart J. 2022 Nov 1;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244. Eur Heart J. 2022. PMID: 36017568 No abstract available.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH; ESC Scientific Document Group. Lyon AR, et al. Eur Heart J Cardiovasc Imaging. 2022 Sep 10;23(10):e333-e465. doi: 10.1093/ehjci/jeac106. Eur Heart J Cardiovasc Imaging. 2022. PMID: 36017575 No abstract available.
[Update on myocarditis].
Moonen M, Lancellotti P. Moonen M, et al. Rev Med Liege. 2018 May;73(5-6):269-276. Rev Med Liege. 2018. PMID: 29926565 Free article. Review. French.
[Cancer therapy-induced cardiotoxicity].
Frères P, Poncin A, Moonen M, Josse C, Oury C, Bours V, Lancellotti P, Jerusalem G. Frères P, et al. Among authors: moonen m. Rev Med Liege. 2016 Sep;71(9):382-387. Rev Med Liege. 2016. PMID: 28383833 Free article. Review. French.
[Beriberi].
Moonen M, Lancellotti P, Betz R, Lambermont B, Piérard L. Moonen M, et al. Rev Med Liege. 2007 Jul-Aug;62(7-8):523-30. Rev Med Liege. 2007. PMID: 17853677 Free article. French.
Cardiac amyloidosis: a review of the literature.
de Marneffe N, Dulgheru R, Ancion A, Moonen M, Lancellotti P. de Marneffe N, et al. Among authors: moonen m. Acta Cardiol. 2022 Oct;77(8):683-692. doi: 10.1080/00015385.2021.1992990. Epub 2022 Jul 19. Acta Cardiol. 2022. PMID: 35852493 Review.
Screening Program of Abdominal Aortic Aneurysm.
Sprynger M, Willems M, Van Damme H, Drieghe B, Wautrecht JC, Moonen M. Sprynger M, et al. Among authors: moonen m. Angiology. 2019 May;70(5):407-413. doi: 10.1177/0003319718824940. Epub 2019 Jan 17. Angiology. 2019. PMID: 30654619 Review.
162 results